Purinoreceptor-mediated current in myocytes from renal resistance arteries

Br J Pharmacol. 2010 Jun;160(4):987-97. doi: 10.1111/j.1476-5381.2010.00714.x.

Abstract

Background and purpose: Ionotropic purinoreceptors (P2X) in renal vascular smooth muscle cells (RVSMCs) are involved in mediating the sympathetic control and paracrine regulation of renal blood flow (RBF). Activation of P2X receptors elevates [Ca(2+)](i) in RVSMCs triggering their contraction, leading to renal vasoconstriction and decrease of RBF. The goal of the present work was to characterize the P2X receptor-mediated ionic current (I(P2X)) and to identify the types of P2X receptors expressed in myocytes isolated from interlobar and arcuate arteries of rat kidney.

Experimental approach: The expression of P2X receptors in isolated RVSMCs was analysed by reverse transcription (RT)-PCR. I(P2X) and membrane potential were recorded using the amphotericin B-perforated patch method.

Key results: RT-PCR analysis on single RVSMCs showed the presence of genes encoding P2X1 and P2X4 receptors. Under voltage clamp conditions, the selective P2X receptor agonist alphabeta-methylene ATP (alphabeta-meATP) evoked I(P2X) similar to that induced by ATP. Under current clamp conditions, both ATP and alphabeta-meATP evoked a spike-like membrane depolarization followed by a sustained depolarization, linking P2X receptors in RVSMCs to sympathetic control of renal vascular tone. A selective antagonist of P2X1 receptors, NF279, reduced I(P2X) amplitude by approximately 65% concentration-dependently manner within the nanomolar to sub-micromolar range. The residual current was resistant to micromolar concentrations of NF279, but was inhibited by sub-millimolar to millimolar concentrations of NF279.

Conclusions and implications: Two types of functional P2X receptors, monomeric P2X1 and heteromeric P2X1/4 receptors, are expressed in RVSMCs. Our study has identified important targets for possible pharmacological intervention in the sympathetic control of renal circulation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / analogs & derivatives
  • Adenosine Triphosphate / pharmacology
  • Animals
  • Arteries / drug effects
  • Arteries / physiology*
  • Kidney / blood supply*
  • Kinetics
  • Male
  • Membrane Potentials* / drug effects
  • Microdissection
  • Muscle, Smooth, Vascular / cytology
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / metabolism*
  • Myocytes, Smooth Muscle / drug effects
  • Myocytes, Smooth Muscle / metabolism
  • Organ Specificity
  • Osmolar Concentration
  • Patch-Clamp Techniques
  • Purinergic P2 Receptor Agonists
  • Purinergic P2 Receptor Antagonists
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Inbred WKY
  • Receptors, Purinergic P2 / genetics
  • Receptors, Purinergic P2 / metabolism*
  • Receptors, Purinergic P2X
  • Receptors, Purinergic P2X4
  • Reverse Transcriptase Polymerase Chain Reaction
  • Suramin / analogs & derivatives
  • Suramin / pharmacology

Substances

  • NF 279
  • P2rx4 protein, rat
  • Purinergic P2 Receptor Agonists
  • Purinergic P2 Receptor Antagonists
  • RNA, Messenger
  • Receptors, Purinergic P2
  • Receptors, Purinergic P2X
  • Receptors, Purinergic P2X4
  • Suramin
  • Adenosine Triphosphate
  • alpha,beta-methyleneadenosine 5'-triphosphate